CN114222567A - Mcl1蛋白抑制剂在制备治疗炎症及神经退行性疾病药物中的应用 - Google Patents

Mcl1蛋白抑制剂在制备治疗炎症及神经退行性疾病药物中的应用 Download PDF

Info

Publication number
CN114222567A
CN114222567A CN202080024094.XA CN202080024094A CN114222567A CN 114222567 A CN114222567 A CN 114222567A CN 202080024094 A CN202080024094 A CN 202080024094A CN 114222567 A CN114222567 A CN 114222567A
Authority
CN
China
Prior art keywords
disease
inflammation
mcl1
umi
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080024094.XA
Other languages
English (en)
Inventor
夏宏光
岑旭峰
许正平
盛静浩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang University ZJU
Original Assignee
Zhejiang University ZJU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang University ZJU filed Critical Zhejiang University ZJU
Publication of CN114222567A publication Critical patent/CN114222567A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)

Abstract

本发明公开了MCL1蛋白抑制剂在制备治疗炎症及神经退行性疾病药物中的应用。本发明提出了MCL1抑制剂UMI‑77对线粒体自噬的诱导作用，通过对急性肝炎，炎症性肠病和APP/PS1小鼠模型中的效果来看，UMI‑77对炎症有显著的抑制效果，对阿尔兹海默症有显著缓解效果。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN202080024094.XA 2019-05-09 2020-04-07 Mcl1蛋白抑制剂在制备治疗炎症及神经退行性疾病药物中的应用 Pending CN114222567A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910386493X 2019-05-09
CN201910386493.XA CN111904958B (zh) 2019-05-09 2019-05-09 Umi-77作为线粒体自噬诱导剂在制备治疗炎症及神经退行性疾病药物中的应用
PCT/CN2020/083442 WO2020224364A1 (zh) 2019-05-09 2020-04-07 Mcl1蛋白抑制剂在制备治疗炎症及神经退行性疾病药物中的应用

Publications (1)

Publication Number Publication Date
CN114222567A true CN114222567A (zh) 2022-03-22

Family

ID=73051393

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910386493.XA Active CN111904958B (zh) 2019-05-09 2019-05-09 Umi-77作为线粒体自噬诱导剂在制备治疗炎症及神经退行性疾病药物中的应用
CN202080024094.XA Pending CN114222567A (zh) 2019-05-09 2020-04-07 Mcl1蛋白抑制剂在制备治疗炎症及神经退行性疾病药物中的应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201910386493.XA Active CN111904958B (zh) 2019-05-09 2019-05-09 Umi-77作为线粒体自噬诱导剂在制备治疗炎症及神经退行性疾病药物中的应用

Country Status (2)

Country Link
CN (2) CN111904958B (zh)
WO (1) WO2020224364A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111904958B (zh) * 2019-05-09 2022-09-13 浙江大学 Umi-77作为线粒体自噬诱导剂在制备治疗炎症及神经退行性疾病药物中的应用
CN113476441B (zh) * 2021-07-09 2023-06-27 暨南大学 Crassifolin A在促进线粒体自噬及治疗神经退行性疾病中的应用
CN115894404A (zh) * 2021-09-22 2023-04-04 杭州天玑济世生物科技有限公司 一类具有萘胺结构的小分子化合物及其应用
CN115894317A (zh) * 2021-09-22 2023-04-04 杭州天玑济世生物科技有限公司 一类具有萘硫酚醚结构的小分子化合物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140235702A1 (en) * 2011-10-06 2014-08-21 Wayne State University Small molecule inhibitors of mcl-1 and the uses of thereof
WO2017027845A1 (en) * 2015-08-12 2017-02-16 Memorial Sloan-Kettering Cancer Center Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases
CN111904958A (zh) * 2019-05-09 2020-11-10 浙江大学 Umi-77作为线粒体自噬诱导剂在制备治疗炎症及神经退行性疾病药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201514760D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
MX2018010678A (es) * 2016-03-04 2019-01-17 Univ Vanderbilt Inhibidores de mcl-1 indolicos sustituidos.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140235702A1 (en) * 2011-10-06 2014-08-21 Wayne State University Small molecule inhibitors of mcl-1 and the uses of thereof
WO2017027845A1 (en) * 2015-08-12 2017-02-16 Memorial Sloan-Kettering Cancer Center Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases
CN111904958A (zh) * 2019-05-09 2020-11-10 浙江大学 Umi-77作为线粒体自噬诱导剂在制备治疗炎症及神经退行性疾病药物中的应用

Also Published As

Publication number Publication date
CN111904958B (zh) 2022-09-13
WO2020224364A1 (zh) 2020-11-12
CN111904958A (zh) 2020-11-10

Similar Documents

Publication Publication Date Title
CN114222567A (zh) Mcl1蛋白抑制剂在制备治疗炎症及神经退行性疾病药物中的应用
Wang et al. Histone deacetylase 4 selectively contributes to podocyte injury in diabetic nephropathy
JP6879980B2 (ja) ウロリチンまたはその前駆体の投与によるオートファジーの増強または寿命の延長
JP6707549B2 (ja) 抗老化化合物及びその使用
Yang et al. Inhibition of miR‐148b ameliorates myocardial ischemia/reperfusion injury via regulation of Wnt/β‐catenin signaling pathway
KR20210137434A (ko) 연령 관련 염증 및 장애를 치료, 예방 또는 역전시키기 위한 조성물 및 방법
CN107405380A (zh) 用于预防听觉损伤的肽及其包含该肽的组合物
US9605026B2 (en) Hydrogen-bond surrogate peptides and peptidomimetics for p53 reactivation
US11471472B2 (en) Use of verbascoside in preparation of drug for preventing or treating glomerular podocyte injured renal disease
EP2975125B1 (en) Microvesicle, and manufacturing method for same
CN110464844B (zh) Alox12抑制剂在制备心脏缺血再灌注损伤治疗药物中的应用
Wen et al. Flavonoids derived from licorice suppress LPS-induced acute lung injury in mice by inhibiting the cGAS-STING signaling pathway
CN112656795A (zh) 防己诺林碱在抗结膜黑色素瘤中的作用机制及应用
Chu et al. Autophagy signaling pathway is a therapeutic target to inhibit GCRV replication
Tao et al. Chitosan-coated artesunate protects against ulcerative colitis via STAT6-mediated macrophage M2 polarization and intestinal barrier protection
WO2023217179A1 (zh) 甘露糖抑制细胞焦亡或减轻化疗药物毒副作用的应用
CN112190712A (zh) 氢巯基氧化酶1激动剂和索拉菲尼联合在制备治疗肝癌细胞中的应用
EA022408B1 (ru) Производные санглиферина и способы их получения
Shao et al. Higenamine improves DSS-induced ulcerative colitis in mice through the Galectin-3/TLR4/NF-κB pathway
CN113528528A (zh) 一种促进耐伊马替尼慢性髓细胞白血病细胞K562/G01凋亡shRNA及其应用
Su et al. N-Cinnamoylpyrrole-derived alkaloids from the genus Piper as promising agents for ischemic stroke by targeting eEF1A1
CN115414485B (zh) uN2CpolyG蛋白抑制剂的用途
CN113337594B (zh) Lpcat1基因在制备治疗肝脏炎症药物及诊断试剂盒中的应用
KR102529484B1 (ko) 스타틴에 의한 고혈당 예방용 약학적 조성물
US20170071994A1 (en) Medicinal ambrosia maritima extracts

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination